[HTML][HTML] Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis?

GS Christodoulatos, M Dalamaga - World journal of clinical …, 2014 - ncbi.nlm.nih.gov
… predictive usefulness as well as therapeutic value for BC. Micro-… have revealed promising
therapeutic approaches via miRNA … predictors and therapeutic targets aiding BC management. …

[HTML][HTML] Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets?

F Lefranc, E Le Rhun, R Kiss, M Weller - Cancer treatment reviews, 2018 - Elsevier
Purpose The purpose of the current review is to highlight, on one hand, the fact that the migratory
pattern of glioma cells is the major obstacle to combat them with chemotherapy, and on …

Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis?

HA Pershadsingh - Expert Opinion on Investigational Drugs, 2004 - Taylor & Francis
… Since PPAR-γ activation can modulate immune function and cellcycle activity, pharmacological
regulation of PPAR-γ-dependent genes appears to be a prime therapeutic target in the …

Antisense therapy in malignant diseases: status quo and quo vadis?

I Tamm - Clinical science, 2006 - portlandpress.com
… Furthermore, it may lead to the identification of new therapeutic targets and provide the
corresponding drug at the same time. Since most tumour cells have a different pattern of gene …

[PDF][PDF] Quo vadis with targeted drugs in the 21st century?

J Bergh - Journal of Clinical Oncology, 2009 - academia.edu
… corresponding metastatic lesions in our routine therapy predictive factors, which indicates
the need for prospective evaluation of TKs (being the presumed targets for TKIs) in metastatic …

Quo Vadis Advanced prostate Cancer Therapy? Novel treatment perspectives and possible future directions

J Kvízová, V Pavlíčková, E Kmoníčková, T Ruml… - Molecules, 2021 - mdpi.com
… in terms of novel diagnostic methods but also of therapeutic ones, as well as to increase the
… androgen deprivation therapy, antiandrogen therapy, photodynamic therapy, photothermal …

Quo vadis—do immunotherapies have a role in glioblastoma?

SC Kurz, PY Wen - Current treatment options in neurology, 2018 - Springer
therapy and effective target recognition. A pilot study evaluating treatment with adoptively
transferred CMV-specific T cells combined with a CMV-specific DC vaccine was found to be …

Quo vadis, Kras?

G Schneider, D Saur - Oncotarget, 2013 - oncotarget.com
… excellent therapeutic target. However, efforts to develop drugs, which directly target mutant
… help to define important tumor entity specific therapeutic targets. In addition, global deletion …

[HTML][HTML] Ocular gene therapy: quo vadis?

WW Hauswirth, L Beaufrere - Investigative ophthalmology & visual …, 2000 - arvojournals.org
… It is this progress that will be reviewed and then placed in the larger context of ocular gene
therapy, quo vadis? To logically review the eye as a gene therapy target, issues regarding …

Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression

CT Meisel, C Porcheri, TA Mitsiadis - Cells, 2020 - mdpi.com
… Since the increase of evidence regarding the involvement of Notch in cancer and specifically
on cancer stem cells, targeting Notch moved into focus as a therapeutic target. Additionally, …